Publications

BiPar Sciences Publications

Poly (ADP-ribose) polymerase-1 (PARP1) inhibitor BSI-201 in combination with temozolomide (TMZ) in malignant glioma
J. O. Blakeley, X. Ye, S. A. Grossman, T. Mikkelsen, M. R. Rosenfeld, C. R. Bradley, T. E. Stallings, A. F. Eichler, L. B. Nabors, S. Desideri, J. G. Supko
ASCO 2010

Pharmacokinetics of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in cerebrospinal fluid (CSF) of a patient with breast cancer with carcinomatous meningitis
M. Castro, L. Li, T. E. Stallings
ASCO 2010

Updated Results of a Randomized Phase II Study Demonstrating Efficacy and Safety of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin in Metastatic Triple-Negative Breast Cancer
J. O'Shaughnessy, C. Osborne, J. Pippen, D. Patt, C. Rocha, V. Ossovskaya, B. Sherman, and C. Bradley
San Antonio Breast Cancer Symposium Annual Meeting, December 2009

Efficacy of BSI-201, a Poly (ADP-ribose) Polymerase-1 (PARP1) inhibitor, in Combination With Gemcitabine/Carboplatin (G/C) in Patients with Metastatic Triple Negative Breast Cancer (TNBC): Results of a Randomized Phase 2 Trial
J. O'Shaughnessy, C. Osborne, J. Pippen, M. Yoffe, D. Patt, G. Monaghan, V. Ossovskaya, C. Rocha, B. Sherman, and C. Bradley
ASCO 2009

BSI-201 enhances the activity of multiple classes of cytotoxic agents and irradiation in Triple Negative Breast Cancer
V. Ossovskaya, L. Li, E.V. Broude, C. Lim, I.B. Roninson, C. Bradley, and B. Sherman. AACR 2009

The Novel Poly(ADP-ribose) Polymerase (PARP-1) Inhibitor BSI-401 has antitumor efficacy and synergizes with oxaliplatin in an orthopic murine model of pancreatic cancer
D. Melisi, V. Ossovskaya, B.M. Sherman, J.L. Abbruzzese, and P.J. Chiao.
ASCO GI Cancers Symposium, January 2009

Triple Negative Metastatic Breast Cancer: A Phase 2, Multi-Center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C) With or Without BSI-201, A PARP Inhibitor
J. O'Shaughnessey, C. Osborne, J. Blum, J. Pippe, M. Yoffe, D. Patt, G. Monaghan, C. Rocha, V. Ossovskaya, B. Sherman, and C. Bradley
San Antonio Breast Cancer Symposium Annual Meeting, December 2008

First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors.
S. Kopetz, M. M. Mita, I. Mok, K. K. Sankhala, J. Moseley, B. M. Sherman, C. R. Bradley, A. W. Tolcher
J Clin Oncol 26: 2008 (suppl; abstr 3577)

A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors.
J. J. Mahany, N. Lewis, E. I. Heath, P. M. LoRusso, M. M. Mita, J. Rodon, A. W. Tolcher, B. M. Sherman, C. R. Bradley, K. P. Papadopoulos  
J Clin Oncol 26: 2008 (suppl; abstr 3579)

Activity of BSI-201, a potent Poly(ADP-ribose) polymerase (PARP1) inhibitor, alone and in combination with topotecan in human ovarian xenografts.
Valeria Ossovskaya, Lingyun Li, Charles Bradley, and Barry Sherman   
AACR 2008, 2311

The novel poly(ADP-ribose) polymerase (PARP) -1 Inhibitor, BSI-401, has antitumor activity and potentiates oxaliplatin cytotoxic activity in human pancreatic cancer.
Davide Melisi, Valeria Ossovskaya, Barry Sherman, James Abbruzzese, and Paul Chiao
AACR 2007, B282

PARP1 Gene is over-expressed in Triple Negative Breast Cancer.
Valeria Ossovskaya, Christopher Alvares, Eric Kaldjian and Barry Sherman   
EJC Supplements 2007; 5(8): 31

PARP1 gene over-expression in primary human cancers: A potential marker for PARP inhibition.
Valeria Ossovskaya, Christopher Alvares, Eric Kaldjian, and Barry Sherman
AACR 2007, C125

Other Resources on PARP and PARP Inhibition in Cancer Therapy

Poly ADP-ribose polymerase-1: an international molecule of mystery.
Woodhouse BC, Dianov GL.
DNA Repair (Amst). 2008 Jul 1;7(7):1077-86

PARP inhibitors for cancer therapy.
Curtin NJ.
Expert Rev Mol Med. 2005 Mar 15;7(4):1-20

Development of PARP inhibitors in oncology.
Rodon J, Iniesta MD, Papadopoulos K.
Expert Opin Investig Drugs. 2009 Jan;18(1):31-43.

DNA repair deficiency as a therapeutic target in cancer.
Martin SA, Lord CJ, Ashworth A.
Curr Opin Genet Dev. 2008 Feb;18(1):80-6

The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y, Calvert H.  Ann
N Y Acad Sci. 2008 Sep;1138:136-45

Understanding and treating triple-negative breast cancer.
Anders C, Carey LA.
Oncology (Williston Park). 2008 Oct;22(11):1233-9; discussion 1239-40, 1243

What is triple-negative breast cancer?
Irvin WJ Jr, Carey LA.
Eur J Cancer. 2008 Dec;44(18):2799-805

Development of therapeutic approaches to triple negative phenotype breast cancer.
Shiu KK, Tan DS, Reis-Filho JS.
Expert Opin Ther Targets. 2008 Sep;12(9):1123-37

Triple negative breast cancer: current understanding of biology and treatment options.
Kang SP, Martel M, Harris LN.  
Curr Opin Obstet Gynecol. 2008 Feb;20(1):40-6